In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:
2) Relapsed first-line treatment:
- a)
Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)
- b)
Progress within 24 months:
- -
‘Go-go’ patients: ibrutinib
- •
Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab
- •
- -
‘Slow-go’ patients: ibrutinib
- •
Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite
- •
- -
